Keeping you up to date on recent developments in oncology, including: New study hints that 3D chromatin architecture a key in childhood leukemia; Recruiting NK cells to the antitumor battle; 3D printing meets the medical isotope business.

Keeping you up to date on recent developments in oncology, including: Cancer mortality rates falling, but incidence rising among women; Camouflage for better nano-treatments for cervical cancer; Deep learning may boost glial segmentation studies.

Keeping you up to date on recent developments in oncology, including: Cost effectiveness of biomarker testing for lung cancer screening eligibility still iffy; Unexpected mechanism, combination possibilities for CDK 4/6 inhibitors; Protons pushing into Peoria; BWXT on the move in Tc-99 production.

Keeping you up to date on recent developments in diagnostics, including: Question of COVID-19 contagion window; A paper-based, portable coronavirus test; Finding the next pandemic threat early on; Anatomy study reveals schizophrenia subtypes.

Keeping you up to date on recent developments in oncology, including: Study identifies two different cancer stem cells in cervical cancer; How cancer cells hibernate…; …And who makes their bed; Blocking trash trashes MSI-hi tumors.

Keeping you up to date on recent developments in oncology, including: Study demonstrates time travel possible for pancreatic cancer; Angle’s Parsotix fares well in new study; New technique boosts utility of organoids; Smart microwaves take on breast cancer.

Keeping you up to date on recent developments in oncology, including: New approach to photothermal treatment beats biofilm problem; Origin story helps ovarian cancer prognosis; Sharper look yields new potential kinase target in ovarian cancer; Autophagy activation may prevent metastasis.

Two of three oncology drugs selected for blockbuster status in the Cortellis Drugs to Watch analysis are antibody-drug conjugates (ADCs), highly targeted cancer therapies designed to leave the healthy cells be and zap the bad ones. What once was a dead end for development has morphed into a competitive space with 57 ADC candidates for cancer indications in phase I or later trials, according to Cortellis.

No matter how effective it is, a drug is worthless if the people who need it can’t afford it. That’s been almost an anthem for patients and policy wonks testifying before U.S. Congress on drug prices.